Leukocyte immunoglobulin-like receptor B2 overexpression as a promising therapeutic target and noninvasive screening biomarker for colorectal cancer

Table 1 Associations between leukocyte immunoglobulin-like receptor B2 and angiopoietin-like protein 2 protein expression and clinicopathological features of colorectal cancer

	LILRB2		P value	ANGPTL2		P value
	Low (n = 19)	High (n = 39)		Low (n = 30)	High (n = 28)
Clinical features
Age (yr)			0.670			0.986
≤ 50	4 (21.1%)	5 (12.8%)		14 (46.7%)	13 (46.4%)
> 50	15 (78.9%)	34 (87.2%)		16 (53.3%)	15 (53.6%)
Sex			1.000			0.473
Male	10 (52.6%)	21 (53.8%)		24 (80.0%)	25 (89.3%)
Female	9 (47.4%)	18 (46.2%)		6 (20.0%)	3 (10.7%)
Histopathological features
Location			0.737			0.065
Right-side colon	2 (10.5%)	7 (17.9%)		2 (6.60%)	7 (25.0%)
Left-side colon	6 (31.6%)	9 (23.1%)		11 (36.7%)	4 (14.3%)
Rectum	11 (57.9%)	23 (59.0%)		17 (56.7%)	17 (60.7%)
Size (cm)			0.224			0.436
> 4.9	7 (36.8%)	21 (53.8%)		13 (43.3%)	15 (53.6%)
≤ 4.9	12 (63.2%)	18 (46.2%)		17 (56.7%)	13 (46.4%)
Pathological type			0.287			0.589
Ulcer	12 (63.2%)	29 (74.4%)		23 (76.7%)	18 (64.3%)
Bulge	6 (31.6%)	5 (12.8%)		5 (16.7%)	6 (21.4%)
Mix	1 (5.20%)	5 (12.8%)		2 (6.60%)	4 (14.3%)
Differentiation			0.009			0.013
Poor	0 (0.00%)	10 (25.6%)		1 (3.40%)	9 (32.1%)
Moderate	15 (78.9%)	27 (69.2%)		25 (83.3%)	17 (60.7%)
High	4 (21.1%)	2 (5.20%)		4 (13.3%)	2 (7.20%)
Vascular involvement			0.001			0.016
Yes	1 (5.30%)	19 (48.7%)		6 (20.0%)	14 (50.0%)
No	18 (94.7%)	20 (51.3%)		24 (80.0%)	14 (50.0%)
Nerve involvement			0.019			0.754
Yes	7 (36.8%)	27 (69.2%)		17 (56.7%)	17 (60.7%)
No	12 (63.2%)	12 (30.8%)		13 (43.3%)	11 (39.3%)
Lymph node metastasis			< 0.001			0.008
Yes	2 (10.5%)	29 (74.4%)		11 (36.7%)	20 (71.4%)
No	17 (89.5%)	10 (25.6%)		19 (63.3%)	8 (28.6%)
Molecular pathology
KRAS			0.186			0.249
+	6 (31.6%)	19 (48.7%)		11 (36.7%)	14 (50.0%)
-	13 (68.4%)	20 (51.3%)		19 (63.3%)	14 (50.0%)
NRAS			0.594			0.613
+	2 (10.5%)	2 (5.10%)		3 (10.0%)	1 (3.60%)
-	17 (89.5%)	37 (94.9%)		27 (90.0%)	27 (96.4%)
PIK3CA			1.000			1.000
+	0 (0.0%)	1 (2.60%)		1 (3.30%)	0 (0.0%)
-	19 (100%)	38 (97.4%)		29 (96.7%)	28 (100%)
BRAF			0.548			1.000
+	0 (0.0%)	2 (5.10%)		1 (3.30%)	1 (3.60%)
-	19 (100%)	37 (94.9%)		29 (96.7%)	27 (96.4%)
MS			1.000			1.000
MSS	18 (94.7%)	37 (94.9%)		28 (93.3%)	27 (96.4%)
MSI-H	1 (5.30%)	2 (5.10%)		2 (6.70%)	1 (3.60%)
Clinical stage
pT			0.001			0.006
T1	0 (0.0%)	0 (0.0%)		0 (0.0%)	0 (0.0%)
T2	7 (36.8%)	1 (2.60%)		7 (23.3%)	1 (3.60%)
T3	11 (57.9%)	27 (69.2%)		21 (70.0%)	17 (60.7%)
T4	1 (5.30%)	11 (28.2%)		2 (6.70%)	10 (35.7%)
pN			< 0.001			0.001
N0	19 (100%)	11 (28.2%)		22 (73.3%)	8 (28.6%)
N1	0 (0.0%)	15 (38.5%)		6 (20.0%)	9 (32.1%)
N2	0 (0.0%)	13 (33.3%)		2 (6.70%)	11 (39.3%)
pM			0.044			0.002
M0	19 (100%)	31 (79.5%)		30 (100%)	20 (71.4%)
M1	0 (0.0%)	8 (20.5%)		0 (0.0%)	8 (28.6%)
pTNM stage			< 0.001			< 0.001
I-II	18 (94.7%)	10 (25.6%)		22 (73.3%)	6 (21.4%)
III-IV	1 (5.30%)	29 (74.4%)		8 (26.7%)	22 (78.6%)

LILRB2: Leukocyte immunoglobulin-like receptor B2; ANGPTL2: Angiopoietin-like protein 2; CRC: Colorectal cancer; MS: Microsatellite state; MSS: Microsatellite stability; MSI-H: Microsatellite instability-high.